News

‘Epidemiologic trends and disparities in diabetes risk factors among LGBTQ+ populations’ was the title of a presentation at the 59th Annual Meeting of the EASD and it highlighted the need for mor...

There is increasing interest in the role of the microbiome in many areas of medicine, including diabetes, in the hope of discovering novel therapeutic applications. A symposium at the 59th Annual Meeting of ...

Recent research suggests that there is much more to obesity than elevated body mass index. The latest findings on the role of liver fat and metabolically healthy obesity were under discussion at the 59th Ann...

The benefits of SGLT-2 inhibitors for people with type 2 diabetes and chronic kidney disease (CKD) have been amply demonstrated in recent years. So is it time to prescribe them to all those who have both con...

The latest research into hypoglycaemia was under discussion at the 59th Annual Meeting of the EASD. The ‘To hell with the hypo’ session covered topics ranging from a tool to predict nocturnal hyp...

Disparities in health burdens were explored at the American Diabetes Association’s 83rd Scientific Sessions. Lisa Buckingham reports. 

What are the barriers to technology use in primary care and how can we overcome them? This question was addressed at the American Diabetes Association’s 83rd Scientific Sessions. Lisa Buckingham report...

As research increasingly focuses on the early stages of type 1 diabetes, a presentation at the American Diabetes Association’s 83rd Scientific Sessions covered the emerging data on the potential of phy...

Intermittent fasting (IF) has gained popularity as a way of losing weight and improving cardiometabolic health. A debate on whether the window for eating within an IF regime is best timed early or late in th...

With an ageing population, it’s increasingly important to understand the impact of diabetes on older adults. Hypoglycaemia was the focus at the American Diabetes Association’s 83rd Scientific Ses...

The microbiome is the latest research frontier in obesity and the latest studies – and future speculation – were under discussion at the recent American Diabetes Association’s 83rd Sci...

Increasing the knowledge of all healthcare professionals involved with diabetes can improve glycaemic outcomes and care transitions. A Diabetes Champion programme was discussed at the American Diabetes Assoc...

Two weekly insulins are well into clinical development, with trials showing promising results so far. An expert panel at the American Diabetes Association’s 83rd Scientific Sessions discussed how ...

There are more people on the move around the world than ever before, so it is crucial to understand the specific factors that affect immigrants’ health. An expert panel discussed the latest resear...

The findings of the SURMOUNT-2 trial were unveiled in a panel discussion at the American Diabetes Association 83rd Scientific Sessions recently. The study showed that weekly tirzepatide leads to signifi...

Optimal medical therapy, as recommended in clinical guidelines, is underused in high-risk patients with type 2 diabetes and cardiovascular disease, heart failure and chronic kidney disease. The COORDINATE-Di...

The impact on calorie intake of portion size, energy density and plant-based and ultra-processed foods was discussed at the American Diabetes Association’s 83rd Scientific Sessions held in San Die...

Chronic kidney disease (CKD) and heart failure in type 2 diabetes were under discussion at the recent Primary Care Diabetes Europe conference. Screening and implementing the latest research need to be priori...

David Matthews, Professor Emeritus in Diabetic Medicine at the University of Oxford, gave the Paul Cromme Award Lecture at the recent Primary Care Diabetes Europe (PCDE) conference in Barcelona. Professor Ma...

Type 2 diabetes is increasingly being diagnosed among people under the age of 40. Early-onset diabetes is associated with an increased risk of complications and requires more intensive intervention, accordin...

Immunotherapy offers new hope to those at risk of type 1 diabetes, with teplizumab being the first approved treatment. Research into identifying those most likely to respond to immunotherapy and which treatm...